DekaBank Deutsche Girozentrale - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2022$607,000
-31.6%
402,100
+10.0%
0.00%
-50.0%
Q4 2021$887,000
-36.2%
365,500
-33.5%
0.00%
-50.0%
Q3 2021$1,390,000
-12.7%
550,0000.0%0.00%
-20.0%
Q2 2021$1,592,000550,0000.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$28,160,0003.29%
Defender Capital, LLC. 4,416,590$3,657,0002.67%
Prescott General Partners LLC 1,851,851$1,534,0000.13%
Laidlaw Wealth Management LLC 107,379$89,0000.06%
Northeast Financial Consultants Inc 523,756$434,0000.05%
Beirne Wealth Consulting Services, LLC 45,000$37,0000.04%
DAFNA Capital Management LLC 95,000$79,0000.03%
Summit X, LLC 30,700$25,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 529,039$438,0000.01%
Keudell/Morrison Wealth Management 10,105$8,0000.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders